Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Drug-induced parkinsonism: A case report

Case Reports Sample Work

Drug-induced parkinsonism (DIP) is characterized by the development of parkinsonian features after exposure to certain medications. This phenomenon was first described as a complication of neuroleptic therapy in 1950. Symptoms of DIP tend to be bilateral and symmetrical in nature and often appear within days; however, the majority of patients with DIP will develop symptoms within three months of starting their medication. In contrast to Parkinson’s disease, DIP does not result from degeneration of the substantia nigra, nor are there specific mechanisms associated with dopamine antagonist receptors (D2).[1]

An adverse drug reaction report with a fatal outcome

This sample belongs to a particular subgroup of case reports: the adverse drug reaction (ADR) report. It describes severe, prolonged parkinsonism in an older man after initiation of paliperidone palmitate long-acting injectable (LAI) antipsychotic therapy, a course complicated by multiple medical events and ending in his death about five months later. The intended readers are psychiatrists, clinical and psychiatric pharmacists and prescribers in general hospitals, and the report's goal is practical: to highlight how renal function, injection site, loading regimen and concomitant medicines may combine to raise exposure to a long-acting drug that cannot be withdrawn quickly.

The document comprises a bibliographic table for the source article, a structured abstract with eight keywords, introduction, case presentation with a medication timeline figure, discussion, conclusion and seven references.

Drug-induced parkinsonism and the problem of long-acting exposure

Drug-induced parkinsonism is the appearance of parkinsonian features, such as bradykinesia, rigidity, tremor and gait disturbance, after exposure to dopamine-blocking medicines. The sample's introduction notes that it was first described as a complication of neuroleptic therapy in 1950, that symptoms tend to be bilateral and symmetrical, and that most cases arise within three months of starting treatment; the abstract puts this at nearly 90%. Unlike Parkinson's disease, it is not caused by degeneration of the substantia nigra.

Long-acting injectables improve adherence, which is why they are widely used in serious mental illness, but their extended pharmacokinetic profile means that an adverse effect may persist for weeks or months after the last dose. The discussion cites clinical trial parkinsonism rates for paliperidone LAI of 8.7% in a 23-week open-label study and 3% in a 15-month double-blind study, compared with 1.8% for placebo, while noting that severe presentations like this one are rare.

Reading the medication timeline alongside the narrative

The case presentation describes a 68-year-old man with a psychiatric history of bipolar I disorder versus cyclothymic disorder, along with hypertension, hyperlipidaemia and coronary artery disease. After admission to an acute care hospital for severe diarrhoea, he was transferred for psychiatric evaluation because of pressured speech, flight of ideas, distractibility, delusional thinking and disorganised thought.

The sample's single figure is a dose–time chart covering roughly the first 55 days, plotting oral risperidone, oral olanzapine and divalproex extended-release on dual axes and marking each paliperidone injection. Read together with the text, it shows:

  • risperidone titrated from 0.25 mg to 8 mg daily, with benztropine added after a stooped posture and shuffling gait appeared;
  • a cross-taper to olanzapine (up to 10 mg daily) and initiation of divalproex at 1250 mg daily on day 34;
  • paliperidone LAI 234 mg, then 156 mg one week later, given while olanzapine was being tapered.

After the second injection the patient developed shuffling gait, bradykinesia, hypophonia, hypomimia, sialorrhoea and cogwheel rigidity, with no acute MRI findings. All neuroleptics were stopped about a month after the first injection. Symptomatic treatment was limited by adverse effects: high-dose diphenhydramine caused sedation and delirium, benztropine provoked a severe allergic reaction, and carbidopa-levodopa was stopped because of dysphagia and feeding tube obstruction. Gastrostomy and later tracheostomy followed, with infections, thromboembolic events, gastrointestinal bleeding and organ failure before his death from cardiorespiratory failure.

Causality assessment and the confounders the authors acknowledge

A credible ADR report must address whether the drug caused the event, and this sample does so in a structured way. The discussion examines exposure: the recommended reduced loading regimen for patients with creatinine clearance of 50–79 mL/min is 156 mg followed by 117 mg, whereas this patient, with a clearance of about 60 mL/min, received 234 mg and 156 mg. It also considers the injection sites, noting that deltoid administration produces higher peak concentrations than gluteal, and a reported pharmacokinetic interaction in which divalproex increases paliperidone exposure with the oral formulation.

The authors then apply the Naranjo adverse drug reaction probability scale, which rates the reaction as "possibly" related to paliperidone LAI, and they list confounders openly: prior risperidone, concurrent olanzapine taper, divalproex (itself linked to parkinsonism in older adults) and the possibility of undiagnosed early Parkinson's disease. A dopamine transporter scan was considered but deferred. This candour is what the CARE guidelines expect when causality is uncertain, and it also aligns with how pharmacovigilance assessors grade individual case safety reports.

Writing up a suspected medication harm for publication

Clinicians and pharmacists preparing an ADR case can adapt several features of this sample:

  1. Plot doses of every relevant medicine against time in a single figure so readers can relate onset to exposure.
  2. Report organ function (here, creatinine clearance) at the time of dosing.
  3. Apply a recognised causality tool and state its result in the discussion.
  4. List alternative explanations and explain why each was or was not excluded.
  5. End with a specific, actionable prescribing message; the sample suggests electronic alerts for renal dose adjustment below a creatinine clearance of 80 mL/min.

Pubrica's case report writing service supports this kind of medication-safety manuscript, and journal selection can identify pharmacy, psychiatry and pharmacovigilance journals that publish ADR reports. Authors should also report suspected reactions through their national pharmacovigilance scheme, independently of publication. This page shows a writing sample and does not provide prescribing advice.

Questions about this sample

What does the Naranjo scale result in this sample mean?

The Naranjo scale scores an adverse event on questions such as timing, response to withdrawal and alternative causes, giving a category from doubtful to definite. The sample reports a result of possibly related to paliperidone LAI, reflecting a plausible temporal link alongside several confounding medicines and conditions.

Why does the report focus on the patient's creatinine clearance?

Paliperidone is cleared largely by the kidneys, and the sample notes that a reduced loading regimen of 156 mg then 117 mg is recommended for a creatinine clearance of 50 to 79 mL/min. The patient, at about 60 mL/min, received 234 mg then 156 mg, which may have produced higher serum concentrations than intended.

What does the medication figure in the sample show?

It is a dose-time chart over about 55 days showing oral risperidone and olanzapine doses on one axis and divalproex extended-release on another, with star markers for the two paliperidone injections. It lets readers see that paliperidone was started during an olanzapine taper and after divalproex had been introduced.

Which alternative explanations does the discussion consider?

It considers prior exposure to risperidone, concurrent olanzapine during the taper, divalproex, which has been associated with parkinsonism in older adults, and possible undiagnosed early Parkinson's disease. A dopamine transporter scan could have helped distinguish degenerative from drug-induced parkinsonism but was deferred because of cost and limited impact on management.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.